

2Q2023 Fact Sheet

Jeisys

Disclaimer

► it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

I. P/L (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Sales	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161			64,266
Cost of Goods sold	4,712	5,913	6,026	7,998	24,649	7,638	10,056	9,160	10,121	36,975	9,557	10,516			20,072
Ratio(%)	27%	31%	30%	33%	30%	30%	33%	32%	32%	32%	33%	30%			31%
Gross profit	12,546	13,326	14,378	16,397	56,647	17,696	20,715	19,482	21,682	79,575	19,548	24,646			44,194
Ratio(%)	73%	69%	70%	67%	70%	70%	67%	68%	68%	68%	67%	70%			69%
SG&A	7,613	7,460	8,184	9,784	33,042	9,147	11,753	11,766	12,874	45,540	11,934	14,998			26,932
Operating profit	4,933	5,865	6,194	6,613	23,604	8,549	8,962	7,716	8,808	34,035	7,614	9,648			17,262
Ratio(%)	29%	30%	30%	27%	29%	34%	29%	27%	28%	29%	26%	27%			27%
Net profit before income tax	-5,657	5,747	6,391	6,613	13,093	8,399	9,366	9,111	7,010	33,886	8,434	8,018			16,452
Net profit	-6,303	5,634	6,135	8,026	13,493	6,512	7,360	7,182	5,958	27,012	6,681	6,249			12,930
Ratio(%)	-37%	29%	30%	33%	17%	26%	24%	25%	19%	23%	23%	18%			20%
EBITDA	5,507	6,413	6,859	7,245	26,024	9,257	9,704	8,333	10,101	37,396	8,619	10,688			19,307
Ratio(%)	32%	33%	34%	30%	32%	37%	32%	29%	32%	32%	30%	30%			30%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by product portfolio (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
HIFU	3,304	3,466	3,601	2,645	13,015	3,628	3,062	5,945	4,645	17,280	4,429	3,617			8,046
RF	3,974	2,994	3,837	5,881	16,686	7,058	9,355	5,923	9,065	31,402	5,841	10,044			15,885
IPL	514	661	946	2,378	4,499	1,234	2,010	1,340	1,359	5,943	1,510	1,250			2,760
LASER	1,591	2,007	2,295	1,797	7,690	2,503	2,596	3,418	2,392	10,908	2,459	2,822			5,281
Consumables	7,260	9,413	9,573	11,069	37,315	10,237	13,120	10,740	11,424	45,521	12,754	14,304			27,057
Others	615	699	153	625	2,091	674	628	1,277	2,918	5,496	2,112	3,124			5,236
Total	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161			64,266

III. Sales by Regional (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Domestic	2,459	2,848	3,093	3,743	12,144	3,433	3,894	4,882	4,737	16,946	4,002	5,625			9,627
Overseas	14,798	16,391	17,311	20,652	69,152	21,901	26,876	23,761	27,066	99,604	25,103	29,536			54,639
Total	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161			64,266

IV. Major Device Sales

Total company (Unit : EA)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
LinearFirm / LinearZ	164	196	212	171	743	238	186	312	236	972	261	191			452
Cumulative Sales	1,599	1,795	2,007	2,178	-	2,416	2,602	2,914	3,150	-	3,411	3,602			-
POTENZA	175	99	108	192	574	300	410	197	325	1,232	164	283			447
Cumulative Sales	636	735	843	1,035	-	1,335	1,745	1,942	2,267	-	2,431	2,714			-

V. B/S (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31
Current assets	41,060	39,180	46,012	54,173	54,173	61,487	67,776	69,877	74,483	74,483	88,589	89,988			
Cash and cash equivalents	19,582	23,263	28,668	34,291	34,291	36,394	32,274	33,627	39,583	39,583	52,017	52,593			
Short-term trade Receivable	5,945	5,144	5,183	6,872	6,872	8,198	11,000	9,433	10,343	10,343	7,017	10,821			
Inventories	6,190	8,171	9,679	10,578	10,578	13,234	18,329	20,423	20,380	20,380	20,328	21,522			
Non-current assets	10,829	11,316	12,468	19,886	19,886	23,692	27,686	35,460	43,568	43,568	37,022	43,646			
Total assets	51,889	50,496	58,481	74,059	74,059	85,178	95,462	105,337	118,052	118,052	125,611	133,634			
Current liabilities	12,957	14,799	14,548	24,027	24,027	24,757	29,097	23,923	26,331	26,331	28,722	27,026			
Non-current liabilities	9,936	8,678	8,569	2,379	2,379	4,040	3,995	10,485	11,579	11,579	11,494	11,022			
Total liabilities	22,893	23,477	23,117	26,405	26,405	28,797	33,092	34,409	37,910	37,910	40,216	38,048			
Issued capital	7,063	7,063	7,130	7,130	7,130	7,130	7,130	7,130	7,130	7,130	7,614	7,638			
Total equity	28,996	27,020	35,364	47,654	47,654	56,381	62,370	70,928	80,141	80,141	85,395	95,586			

Jeisys Medical Inc.

Hang-In Lee (Team leader) / Mail : hilee@jeisys.com

Yong-Shin Kim (Manager) / Mail : yskim@jeisys.com